Recommendation of the President – Altuvoct (efanesoctocog alfa)
On 8 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 112/2025 on the appraisal of drug Altuvoct (efanesoctocog alfa) under the drug program “Prevention of bleeding in children with hemophilia A and B (ICD-10: D66, D67)”
Publication in Public Information Bulletin (BIP) >>